FDA approves once-daily Requip for Parkinson's

NEW YORK London-based GlaxoSmithKline announced Friday that it had received approval from the Food and Drug Administration for Requip XL, a version of its Parkinson’s disease drug.

Requip is used to treat the symptoms of Parkinson’s disease, including tremors and slowness of movement, as well as symptoms of restless legs syndrome. Requip XL is a once-daily reformulation of the drug that treats only Parkinson’s.

Requip had sales of $679.4 million in 2007, according to GSK financial data originally stated in British pounds (1 pound = $1.96).